ChAdOx1-HBV

Arbutus Biopharma will present five abstracts at EASL Congress 2025, showcasing data on imdusiran and AB-101 for chronic hepatitis B treatment, including one late-breaker abstract.

Arbutus Biopharma plans to initiate a Phase 2b clinical trial of imdusiran, combined with interferon and nucleos(t)ide analogue therapy, in the first half of 2025 for cHBV.

Virion Therapeutics' Phase 1b trial of VRON-0200 has completed enrollment for the first two cohorts, involving 27 chronic hepatitis B patients on antiviral therapy.

Barinthus Biotherapeutics has announced a strategic shift towards immunology and inflammation (I&I) indications, prioritizing the development of VTP-1000 for celiac disease and postponing further development of VTP-300 for chronic hepatitis B until a partner is found. The company also revealed a financial restructuring plan, including a significant workforce reduction and the closure of its U.K. site, to extend its cash runway to the start of 2027.

GigaGen Inc. has initiated Phase 1 clinical trials for GIGA-2339, a groundbreaking recombinant polyclonal antibody therapy targeting chronic hepatitis B virus (HBV) infection. This innovative treatment, designed to target the Hepatitis B surface antigen (HBsAg), represents a potential breakthrough in achieving a functional cure for the 296 million people affected by chronic HBV worldwide.